The latest news from the benefits and retirement industry

Stay up to date on the issues impacting the industry and be the first to hear about news and changes at Rael & Letson.

Retiree Health | Health Benefits

The rules that bind: Actuarial standards of practice and the actuarial board of counseling & discipline

Why can't an actuary make up any number for a retiree health valuation liability - what's it matter?! Learn why it does matter if the actuary wants to stay an actuary.

Read more
Health Benefits | PBM Consulting

Managing GLP-1 plan exclusions

High claims costs and the high demand of popular weight loss medications can lead to necessary plan exclusions, but is exclusion the right path?

Read more
Health Benefits | Retiree Health

Retiree Health Plans 101

Wes Yoder discusses challenges plan sponsors face when introducing and managing retiree health and welfare plans in Benefits Magazine.

Read more
Health Benefits | PBM Consulting

Time to review your Pharmacy Benefit Manager contract?

Need to benchmark your current agreement? Help negotiate a favorable deal? Find lower cost options for expensive medications? We can help.

Read more
Health Benefits | Retiree Health

Retiree benefit costs and options

How to mitigate retiree costs as subsidy levels continue to grow over time.

Read more
Health Benefits

Primary care delivery alternatives

Off and near site clinics could create opportunities to provide a more robust primary care experience and lower overall health care costs.

Read more
Health Benefits

Provider price and quality transparency

Equip your members and employees with the tools they need to be educated healthcare consumers.

Read more
Health Benefits

Is your telemedicine benefit working?

Video and audio access to a physician injury on a 24/7 basis has become a prominent feature among health plans. But is it working?

Read more
Health Benefits | PBM Consulting

Biosimilars could reduce pharmacy costs

Biologics represent a hefty portion of pharmaceutical spending in the U.S., yet more affordable biosimilars remain underutilized.

Read more